sponsored

TGA grants a new indication for shingles vaccine

Now available for adults 18 or older at increased risk of herpes zoster

The TGA has approved an expanded indication of the newest shingles vaccine, Shingrix, to prevent herpes zoster and postherpetic neuralgia in adults 18 years and older who are at increased risk of herpes zoster.

vaccination

Until now, zoster vaccine has only been licensed in Australia for use in adults 50 years and older using either one of two vaccines. They are Shingrix (GlaxoSmithKline), an adjuvanted recombinant varicella zoster vaccine requiring two doses and Zostavax (Merck), a live attenuated single dose vaccine.

However,

Latest